Login to Your Account

Medgenics Set for U.S. Trial of Autologous EPO Biopump

By Nuala Moran
Staff Writer

Wednesday, May 23, 2012
LONDON – Medgenics Inc. got the go-ahead for the first U.S. trial of its autologous biopump technology, with the FDA approving a Phase IIb trial of Epodure, an implant of a patient's own skin that has been engineered to manufacture erythropoietin (EPO).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription